Q2 EPS Estimate for United Therapeutics Lowered by Analyst

United Therapeutics Co. (NASDAQ:UTHR) – Research analysts at HC Wainwright dropped their Q2 2025 EPS estimates for United Therapeutics in a report issued on Monday, May 5th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings of $7.02 per share for the quarter, down from their previous estimate of $7.39. HC Wainwright has a “Buy” rating and a $425.00 price target on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. HC Wainwright also issued estimates for United Therapeutics’ Q3 2025 earnings at $7.03 EPS and Q4 2025 earnings at $6.63 EPS.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company’s quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.17 earnings per share.

Several other brokerages also recently commented on UTHR. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Bank of America raised shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 price objective for the company in a research note on Monday, April 21st. JPMorgan Chase & Co. cut their target price on United Therapeutics from $355.00 to $350.00 and set an “overweight” rating on the stock in a research note on Thursday, May 1st. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday. Finally, UBS Group increased their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $392.00.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $298.70 on Tuesday. The stock has a market capitalization of $13.47 billion, a P/E ratio of 13.12, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58. United Therapeutics has a one year low of $256.08 and a one year high of $417.82. The business’s 50 day simple moving average is $301.56 and its two-hundred day simple moving average is $343.64.

Insider Buying and Selling

In related news, Director Tommy G. Thompson sold 2,500 shares of the business’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now owns 8,480 shares of the company’s stock, valued at $2,703,424. The trade was a 22.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $956,195.85. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 75,500 shares of company stock valued at $24,245,880 over the last ninety days. Company insiders own 11.90% of the company’s stock.

Institutional Trading of United Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. World Investment Advisors LLC purchased a new stake in shares of United Therapeutics in the third quarter worth $393,000. Franklin Resources Inc. grew its position in United Therapeutics by 97.7% during the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after purchasing an additional 123,929 shares during the last quarter. GAMMA Investing LLC increased its stake in United Therapeutics by 29.0% during the 4th quarter. GAMMA Investing LLC now owns 752 shares of the biotechnology company’s stock valued at $265,000 after purchasing an additional 169 shares in the last quarter. Everence Capital Management Inc. purchased a new position in United Therapeutics in the fourth quarter worth about $487,000. Finally, CWA Asset Management Group LLC bought a new position in shares of United Therapeutics in the fourth quarter worth approximately $1,914,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.